CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients.
Saved in:
| Title: | CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients. |
|---|---|
| Authors: | Zhou S, Xu X, Cuo J, Sun C, Hou Y, Wang X, Nana D, Weixun S |
| Source: | Clinical laboratory [Clin Lab] 2026 May 01; Vol. 72 (5). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Clinical Laboratory Publications Country of Publication: Germany NLM ID: 9705611 Publication Model: Print Cited Medium: Internet ISSN: 1433-6510 (Print) Linking ISSN: 14336510 NLM ISO Abbreviation: Clin Lab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
